ClinicalTrials.gg
Not yet recruitingNCT07409285EMBRACEUpdated Feb 13, 2026

The EMBRACE Registry: European Post-Market Registry for Catheter Based Mitral Valve Replacement

An observational study in Mitral Regurgitation, sponsored by HighLife SAS. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by HighLife SAS · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 81 studies in Mitral Valve Insufficiency with a site in Germany — 24 open to participants now, 32 under way, none of them phase 3. Mitral Valve Insufficiency · Germany.

Planned enrollment
23rd of 33
150 · median 214
Started
2026
with 3 others
Observational
33 of 81
12 open now
Primary completion
2029-04
later than 19 of 31 live
Registered
79th of 81
by date
Lead sponsor
4 of 81
HighLife SAS

Among the 81 studies in Mitral Valve Insufficiency with a site in Germany, this one is the 23rd largest by planned enrollment of the 33 observational ones that give a count, is one of 4 that started in 2026, is one of 33 observational ones, reaches primary completion later than 19 of the 31 other live ones, and was the 79th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

24 of the 81 studies in Mitral Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Mitral Valve Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

Post-market registry for post-market surveillance, as part of the post-market plan, for the HighLife transcatheter, transseptal, mitral valve replacement system in a real world commercial setting.

03

Conditions studied

  • Mitral Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Per Instruction For Use (IFU): Adult patients suffering from symptomatic moderate-severe or severe MR who are unsuitable for surgical repair/replacement and transcatheter edge-to-edge repair, as deemed by a multi-disciplinary heart team.

Eligibility criteria

Inclusion Criteria: Participants must fulfill all following inclusion criteria in order to be included in the post market registry:

  1. Participant is indicated for the HighLife TSMVR system per the current approved Instructions For Use (IFU)

    • Participant (≥ 18 years age) with severe or moderately severe mitral valve regurgitation (MR) due to primary (i.e. degenerative) and/or secondary (i.e. functional MR.
    • (LVEF) ≥ 30%
    • Left ventricular end-diastolic dimension (LVEDD) ≤ 70 mm
  2. Based on the assessment of the local multidisciplinary heart team, the participant is:

    1. unsuitable for heart surgery (mitral valve repair or replacement)
    2. unsuitable for treatment with transcatheter edge-to-edge repair (complex TEER anatomy)
    3. eligible to receive the HighLife TSMVR system per the current approved Instructions For Use (IFU) and as assessed by the local heart team

Exclusion Criteria: Participants will be excluded from the post market registry as per the current approved Instructions For Use (IFU) if any of the following criteria is met:

  1. Significantly calcified mitral valves;
  2. Severe mitral annular calcification
  3. Narrow femoral arteries that don't allow the passage of 18F sheaths;
  4. More than 80 cm between the aortic valve and the femoral access;
  5. Allergies to TSMV or SAI components (bovine tissue, Nitinol, polyester, polyethylene, PTFE);
  6. Intolerance to anticoagulation/antiplatelet regimens or procedural anticoagulation;
  7. Active bacterial endocarditis or other active infections;
  8. Allergies to contrast media;
  9. Previous implanted aortic valve prosthesis;
  10. Evidence of intracardiac mass, thrombus, or vegetation.
  11. Participant enrolled in another clinical study that may impact the follow-up or results of this study.
  12. Participant has other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, may limit the patient's ability to participate in the clinical study or to comply with follow-up requirements.
  13. Tricuspid valve disease requiring intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Commercial patients

    That meet the criteria as outlined in the IFU, and who are scheduled to have the HighLife procedure

06

What researchers measure

Primary outcomes

  1. Rate of Technical Success

    To measure the rate of subjects that meet the definition of Technical success defined as an alive participant at exit from procedure room, with all of the following: * Successful vascular access, delivery and retrieval of the HighLife delivery systems * Deployment and correct positioning of the HighLife 28mm bio-prosthesis * Freedom from additional emergency surgery or re-intervention related to the device or access procedure, that occurred (was initiated) during the procedure

    Time frame: At exit from procedure room

  2. Rate of Device Success

    To measure the rate of subjects that meet the definition of Device safety, defined as the freedom of major adverse events at 30 days, as follows: * All-cause mortality * Myocardial infarction * Major/disabling stroke * Life-threatening bleeding (MVARC scale) * Major access and vascular complications * Stage 2 or 3 acute kidney injury (includes dialysis) * Any mitral valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention * Severe hypotension, heart failure or respiratory failure requiring intravenous vasopressors or invasive or mechanical heart failure treatments such as ultrafiltration or hemodynamic assist devices, including intra-aortic balloon pumps or left ventricular or biventricular assist devices for ≥ 48 hours, or prolonged intubation for ≥ 48 hours

    Time frame: 30 days

  3. Primary Performance Endpoint

    Rate of Total Mitral Regurgitation reduction to 1+ or less assessed by transthoracic echo (TTE), and as analyzed by an independent Core Lab

    Time frame: 30 days

Secondary outcomes

  1. Procedural Mortality

    Where patient died during the procedure before exiting the procedure room

    Time frame: At exit from the procedure room

  2. All-cause mortality

    Patient death due to any cause

    Time frame: 30 days, 6 months, 12 months, 1, 2, and 3 year

  3. Reoperation

    To include conversion to surgery, reintervention to surgery or non-surgical procedure

    Time frame: 30 days

  4. Disabling stroke

    Meeting the criteria of disabling versus non-disabling stroke, as defined per MVARC guidelines, to include if ischemic or hemorrhagic

    Time frame: 30 days, 6 months, 1, 2, 3 years

  5. New onset conduction disturbance in the heart

    This would be a heart conduction disturbance requiring a permanent pacemaker

    Time frame: 30 days

  6. Heart Failure Hospitalization

    This would be a heart failure hospitalization, defined per the MVARC guidelines.

    Time frame: 30 days, 6 and 12 months, 1, 2, 3 years

  7. Freedom from left ventricular outflow tract obstruction (LVOTO)

    Mean LVOT gradient ≥ 10 mmHg, as measured by transthoracic echo (TTE), and as analyzed by an independent Core Lab

    Time frame: 30 days

  8. Freedom from paravalvular leak (PVL), > 1+

    This would be a leak around the HighLife valve, as assessed by transthoracic echo (TTE), and analyzed by an independent Core Lab

    Time frame: 30 days

  9. Annualized rate of Heart Failure Hospitalization (HFH)

    An analysis performed by the biostatistician, to evaluate how often a patient experienced HFH in a year.

    Time frame: 1, 2, 3 years

  10. Total reduction of mitral regurgitation (MR) to 1+ or less

    Measure by transthoracic echo (TTE), and as analyzed by an independent Core Lab

    Time frame: 30 days, 6 months, 1, 2, 3 years

  11. Long term durability of the HighLife valve

    That the original HighLife device remains implanted, free from structural valve dysfunction (e.g. residual MR ≥2+ in the presence of morphological deterioration (e.g., torn, flail, or frozen leaflet, calcification, fracture, migration or embolization, device detachment), as assessed by transthoracic echo (TTE) and analyzed by an independent Core Lab, or as adjudicated by a Clinical Events Committee (CEC).

    Time frame: 3 years

  12. KCCQ score (mean) improvement

    Mean improvement in the KCCQ Quality of Life Questionnaire (short form), comparing Baseline to 1 year

    Time frame: 1 year

  13. Improvement in six minute walk test (6MWT)

    Measuring the number of meters a patient can walk in 6 minutes, comparing Baseline to 1 year

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — This will still need to be confirmed and discussed internally.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Apr 2029, 37 months later.

Of 85 observational studies under Mitral Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 192. This study's planned 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2026
First posted
Feb 13, 2026
StartEst.
Mar 14, 2026
Primary completionEst.
Apr 15, 2029
CompletionEst.
Apr 15, 2031
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07409285
Lead sponsor
HighLife SAS
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Mar 14, 2026 (estimated)
Primary completion
Apr 15, 2029 (estimated)
Completion
Apr 15, 2031 (estimated)
Last update
Feb 13, 2026

Study contacts

Vanessa Gallois
Contact
vgallois@highlifemed.com
+33 6 68 77 34 77

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion